advanced urothelial carcinoma clinical trials results

atezolizumab versus chemotherapy
IMvigor211,
NCT02302807
atezolizumab
versus
chemotherapy
patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimenopen label
pembrolizumab versus investigator’s choice of chemotherapy
KEYNOTE-045, 2017
NCT02256436
pembrolizumab
versus
investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine
patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapyopen-label